AgingResearch.NewsJoin free

BFAR

Gene

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

Effects

2

CD8+ T cell antitumor activity

downin mice1

1 study

  1. BFAR impairs CD8+ T cell antitumor activity in mice.

    “Targeting BFAR either through Bfar knockout or treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8+ T cells”

    Animalsshown by Bfar knockoutCD8+ T cells

    Age-related decline in CD8⁺ tissue resident memory T cells compromises antitumor immunity

    Nature aging26 Nov 2024

cytokine-induced JAK2 signaling

downin mice1

1 study

  1. BFAR inhibits cytokine-induced JAK2 signaling in mice.

    “BFAR suppressed cytokine-induced JAK2 signaling by activating JAK2 deubiquitination, thereby limiting downstream STAT1-mediated TRM reprogramming.”

    Animalsthrough activation of JAK2 deubiquitinationCD8+ T cells

    Age-related decline in CD8⁺ tissue resident memory T cells compromises antitumor immunity

    Nature aging26 Nov 2024

Latest

Related